VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: A-002, varespladib methylDrug: Placebo
- Registration Number
- NCT01130246
- Lead Sponsor
- Anthera Pharmaceuticals
- Brief Summary
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
- Detailed Description
A double-blind randomized parallel group placebo controlled study in subjects presenting with an ACS. Up to 6500 subjects will be randomized to receive either A-002 500 mg once daily (QD) or placebo tablets in addition to atorvastatin QD and standard of care. Treatment will be 16 weeks in duration. The dose of atorvastatin shall be adjusted after 8 weeks if subject's LDL-C is ≥100 mg/dL, but otherwise must remain stable throughout the16-week duration of study. The survival status for all enrolled subjects will be ascertained 6 months after they complete the study.
Randomization must occur within ≤96 hours of hospitalization for the index ACS event, or if already hospitalized, within ≤96 hours of index event diagnosis. Follow-up visits will occur on Weeks 1, 2, 4, 8, and 16. A 6 month follow-up visit will also occur.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 5189
-
Men and women ≥40 years of age
-
Written informed consent from the subject
-
A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI)
Unstable angina is defined as:
- Chest pain symptomatic of ischemia or angina occurring at rest or on minimal exertion with a pattern of increasing frequency or severity, lasting >10 minutes and consistent with myocardial ischemia within 24 hours prior to hospitalization and
- New or dynamic ST-segment depression or prominent T-wave inversion changes in at least 2 contiguous leads and
- In addition subjects meeting the above criteria for unstable angina must also have either troponin I, troponin T or CKMB above the LLD but below the 99th percentile of the upper reference limit (URL) and not due to cardioversion or underlying cardiovascular (CHF, cardiomyopathy) or renal disease
NSTEMI is defined as:
- Chest pain symptomatic of ischemia
- No electrocardiogram (ECG) changes, or ST-depression, or T wave changes(i.e., no new Q waves on serial ECGs)and
- Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB isoenzyme > URL
STEMI is defined as:
- Chest pain symptomatic of ischemia
- ST segment elevation and associated T wave changes or ST-segment elevation of at least 2 mm in 2 contiguous leads, either of which persisting for longer than 15 minutes and
- Increase in cardiac troponin > local limit for the definition of myocardial infarction or increase in CK-MB >URL
-
All subjects must have the presence of at least one of the following risk factors:
-
Diabetes Mellitus or
-
Presence of any 3 of the following characteristics of metabolic syndrome
- Waist circumference >102 cm in males, >88 cm in females
- Serum triglycerides ≥150 mg/dL (≥1.7 mmol/L)
- HDL-C <40 mg/dL (<1 mmol/L) in males, <50 mg/dL (<1.3 mmol/L) in females
- Blood pressure ≥130/85 mmHg
- Plasma glucose ≥110 mg/dL (≥6.1 mmol/L) or
-
history of cerebrovascular disease (stroke or TIA) or
-
history of peripheral vascular disease or
-
previous CABG or
-
previous documented myocardial infarction or
-
previous coronary revascularization
-
-
Subjects must be randomized within ≤96 hours of hospital admission for the index event, or if already hospitalized, within ≤96 hours of index event diagnosis
-
Revascularization, if required or planned, must occur prior to randomization
- Subjects enrolled in another experimental (interventional)protocol within the past 30 days prior to Screening.
- Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision or radiation therapy (e.g. chemotherapy)
- The presence of any severe liver disease with cirrhosis, active hepatitis, active chronic hepatitis, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 x ULN, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
- Active cholecystitis, gall bladder symptoms, or any hepatobiliary abnormalities
- The presence of severe renal impairment (creatinine clearance [CrCl] <30 mL/min or creatinine >3 x ULN),nephrotic syndrome, or subjects undergoing dialysis
- Uncontrolled diabetes mellitus (known hemoglobin A1c [HbA1c] >11% within the last 1 month prior to Screening)
- Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or females of childbearing potential who have a positive pregnancy test during screening evaluation. Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double barrier method (diaphragm with spermicidal foam or jelly, or a condom).
- Subjects who have a history of alcohol or drug abuse within 1 year of study entry
- Subjects living too far from participating center or unable to return for follow-up visits
- Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
- Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), or tuberculosis infection
- Acute bacterial, fungal or viral infection
- Subjects currently taking drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
- Subjects with New York Heart Association (NYHA) Class III or IV heart failure, or if known, left ventricular ejection fraction (LVEF) <30
- Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral stenosis or mitral regurgitation
- Ventricular arrhythmias requiring chronic drug treatment or implantable cardioverter-defibrillator (ICD)
- Subjects with no stenosis or stenosis <50% on angiography, if known
- Subjects with a pacemaker or persistent left bundle branch block (LBBB)
- Fasting triglyceride levels of ≥400 mg/dL (4.5 mmol/L)
- Subjects who have a history of statin intolerance or a significant myopathy or rhabdomyolysis with any lipid altering drugs
- Subjects currently treated with the maximum labeled dose of a statin and not at LDL-C target for their level of risk as defined by NCEP ATP III
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A-002 500 mg A-002, varespladib methyl Once daily oral administration Matched Placebo Placebo Once daily oral administration
- Primary Outcome Measures
Name Time Method Primary Objective of the Study 16 weeks To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring hospitalization.
- Secondary Outcome Measures
Name Time Method Secondary Objective of the Study 2, 4, 8, 16 weeks and 6 months To determine whether A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin and standard of care for reducing the occurrence of the hazard of the combined endpoint of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring hospitalization or multiple occurrences of the non-fatal components of the composite primary endpoint.
Trial Locations
- Locations (361)
Investigator Site 1018
🇺🇸York, Pennsylvania, United States
Investigator Site 2020
🇨🇦Lévis, Quebec, Canada
Investigator Site 1114
🇺🇸Macon, Georgia, United States
Investigator Site 6111
🇦🇺Adelaide, South Australia, Australia
Investigator Site 1107
🇺🇸Danville, Pennsylvania, United States
Investigator Site1110
🇺🇸Atlanta, Georgia, United States
Investigator 1141
🇺🇸Cleveland, Ohio, United States
Investigator Site 9107
🇮🇳Kolkata, West Bengal, India
Investigator Site 3912
🇮🇹Colleferro, Italy
Investigator Site 3910
🇮🇹Ferrara, Italy
Investigator Site 4816
🇵🇱Stalowa Wola, Poland
Investigator Site 4806
🇵🇱Warszawa, Poland
Investigator Site 7004
🇷🇺Novosibirsk, Russian Federation
Investigator Site 7008
🇷🇺St. Petersburg, Russian Federation
Investigator Site 7010
🇷🇺St. Petersburg, Russian Federation
Investigator Site 3416
🇪🇸Pamplona, Navarra, Spain
Investigator Site 3408
🇪🇸Vigo, Pontevedra, Spain
Investigator Site 3425
🇪🇸Galdakao, Vizcaya, Spain
Investigator Site 3434
🇪🇸Sevilla, Spain
Investigator Site 1136
🇺🇸Novi, Michigan, United States
Investigator Site 1027
🇺🇸Kalispell, Montana, United States
Investigator Site 1016
🇺🇸Tupelo, Mississippi, United States
Investigator Site 1025
🇺🇸Tyler, Texas, United States
Investigator Site 1139
🇺🇸Layton, Utah, United States
Investigator Site 2067
🇨🇦Hamilton, Ontario, Canada
Investigator Site 1130
🇺🇸Houston, Texas, United States
Investigator Site 2058
🇨🇦London, Ontario, Canada
Investigator Site 4205
🇨🇿Plzen, Czech Republic
Investigator Site 9504
🇬🇪Tbilisi, Georgia
Investigator Site 9505
🇬🇪Tbilisi, Georgia
Investigator Site 9501
🇬🇪Tbilisi, Georgia
Investigator Site 9506
🇬🇪Tbilisi, Georgia
Investigator Site 9503
🇬🇪Tbilisi, Georgia
Investigator Site 4904
🇩🇪Bielefeld, Germany
Investigator Site 4912
🇩🇪Erfurt, Germany
Investigator Site 3607
🇭🇺Szolnok, Szolnok Megye, Hungary
Investigator Site 3920
🇮🇹Novara, Italy
Investigator Site 1046
🇺🇸Minneapolis, Minnesota, United States
Investigator Site 1033
🇺🇸Minneapolis, Minnesota, United States
Investigator Site 9105
🇮🇳New Delhi, Delhi, India
Investigator Site 6130
🇦🇺Perth, Western Australia, Australia
Investigator Site 1034
🇺🇸Duluth, Minnesota, United States
Investigator Site 6125
🇦🇺Perth, Western Australia, Australia
Investigator Site 1108
🇺🇸Fargo, North Dakota, United States
Investigator Site 3413
🇪🇸Majadahonda, Madrid, Spain
Investigator Site 1079
🇺🇸Aurora, Colorado, United States
Investigator Site 1140
🇺🇸Wheat Ridge, Colorado, United States
Investigator Site 3420
🇪🇸Coslada, Madrid, Spain
Investigator Site 1006
🇺🇸Colorado Springs, Colorado, United States
Investigator Site 1054
🇺🇸Littleton, Colorado, United States
Investigator Site 3419
🇪🇸Fuenlabrada, Madrid, Spain
Investigator Site 1064
🇺🇸Birmingham, Alabama, United States
Investigator Site 1063
🇺🇸Birmingham, Alabama, United States
Investigator Site 1065
🇺🇸Birmingham, Alabama, United States
Investigator Site 1050
🇺🇸Denver, Colorado, United States
Investigator Site 1045
🇺🇸Denver, Colorado, United States
Investigator Site 1026
🇺🇸Oklahoma City, Oklahoma, United States
Investigator Site 1004
🇺🇸Oklahoma City, Oklahoma, United States
Investigator Site 1122
🇺🇸Portland, Oregon, United States
Investigator Site 1032
🇺🇸Omaha, Nebraska, United States
Investigator Site 1133
🇺🇸Mobile, Alabama, United States
Investigator Site 1020
🇺🇸Huntsville, Alabama, United States
Investigator Site 1005
🇺🇸Torrance, California, United States
Investigator Site 1132
🇺🇸Escondido, California, United States
Investigator Site 1019
🇺🇸Tucson, Arizona, United States
Investigator Site 1087
🇺🇸Mission Viejo, California, United States
Inevestigator Site 1074
🇺🇸Washington, District of Columbia, United States
Investigator Site 1111
🇺🇸Hartford, Connecticut, United States
Investigator Site 1061
🇺🇸Fort Collins, Colorado, United States
Investigator Site 1117
🇺🇸Washington, District of Columbia, United States
Investigator Site 1030
🇺🇸Washington, District of Columbia, United States
Investigator Site 1112
🇺🇸Ft. Lauderdale, Florida, United States
Investigator Site 1049
🇺🇸Lakeland, Florida, United States
Investigator Site 1095
🇺🇸Tallahassee, Florida, United States
Investigator Site 1124
🇺🇸Miami Beach, Florida, United States
Investigator Site 1069
🇺🇸New Orleans, Louisiana, United States
Investigator Site 1086
🇺🇸Naperville, Illinois, United States
Investigator Site 1125
🇺🇸Oak Lawn, Illinois, United States
Investigator Site 1044
🇺🇸Covington, Louisiana, United States
Investigator Site 1011
🇺🇸Augusta, Georgia, United States
Investigator Site 1066
🇺🇸New Orleans, Louisiana, United States
Investigator Site 1060
🇺🇸Flint, Michigan, United States
Investigator Site 1048
🇺🇸Traverse City, Michigan, United States
Investigator Site 1057
🇺🇸Johnson City, New York, United States
Investigator Site 1100
🇺🇸Gastonia, North Carolina, United States
Investigator Site 1101
🇺🇸Charlotte, North Carolina, United States
Investigator Site 1075
🇺🇸Winston-Salem, North Carolina, United States
Investigator Site 1123
🇺🇸Wilmington, North Carolina, United States
Investigator Site 1024
🇺🇸Canton, Ohio, United States
Investigator Site 1131
🇺🇸Mansfield, Ohio, United States
Investigator Site 1143
🇺🇸Cleveland, Ohio, United States
Investigator Site 1134
🇺🇸Lancaster, Pennsylvania, United States
Investigator Site 1072
🇺🇸Providence, Rhode Island, United States
Investigator Site 1029
🇺🇸Doylestown, Pennsylvania, United States
Investigator Site 1038
🇺🇸Rapid City, South Dakota, United States
Investigator Site 1115
🇺🇸Dallas, Texas, United States
Investigator Site 1138
🇺🇸Sioux Falls, South Dakota, United States
Investigator Site 1040
🇺🇸Dallas, Texas, United States
Investigator Site 1037
🇺🇸Houston, Texas, United States
Investigator Site 1056
🇺🇸Harrisonburg, Virginia, United States
Investigator Site 1043
🇺🇸Richmond, Virginia, United States
Investigator Site 1083
🇺🇸Norfolk, Virginia, United States
Investigator Site 1042
🇺🇸Marshfield, Wisconsin, United States
Investigator Site 6114
🇦🇺Gosford, New South Wales, Australia
Investigator Site 6106
🇦🇺Canberra, Australian Capital Territory, Australia
Investigator Site 6120
🇦🇺Kingswood, New South Wales, Australia
Investigator Site 6113
🇦🇺Cairns, Queensland, Australia
Investigator Site 6123
🇦🇺Nambour, Queensland, Australia
Investigator Site 6103
🇦🇺Elizabeth Vale, South Australia, Australia
Investigator Site 6122
🇦🇺Hobart, Tasmania, Australia
Investigator Site 6124
🇦🇺Bedford Park, South Australia, Australia
Investigator Site 6129
🇦🇺Epping, Victoria, Australia
Investigator Site 6127
🇦🇺Heidelberg, Victoria, Australia
Investigator Site 6101
🇦🇺Kogarah, Australia
Investigator Site 6118
🇦🇺Brisbane, Australia
Investigator Site 6126
🇦🇺Geelong, Australia
Investigator Site 2069
🇨🇦Calgary, Alberta, Canada
Investigator Site 6121
🇦🇺New Lambton, Australia
Investigator Site 6108
🇦🇺So Australia, Australia
Investigator Site 6105
🇦🇺Melbourne, Australia
Investigator Site 6110
🇦🇺Nedlands, Australia
Investigator Site 6119
🇦🇺South Port, Australia
Investigator Site 2065
🇨🇦Edmonton, Alberta, Canada
Investigator Site 2064
🇨🇦Edmonton, Alberta, Canada
Investigator Site 2073
🇨🇦Red Deer, Alberta, Canada
Investigator Site 2068
🇨🇦New Westminister, British Columbia, Canada
Investigator Site 2059
🇨🇦Kelowna, British Columbia, Canada
Investigator Site 2057
🇨🇦Vancouver, British Columbia, Canada
Investigator Site 2048
🇨🇦Halifax, Nova Scotia, Canada
Investigator Site 2066
🇨🇦Surrey, British Columbia, Canada
Investigator Site 2063
🇨🇦Victoria, British Columbia, Canada
Investigator Site 2070
🇨🇦Saint John, Newfoundland and Labrador, Canada
Investigator Site 2072
🇨🇦Sydney, Nova Scotia, Canada
Investigator Site 2075
🇨🇦Kitchener, Ontario, Canada
Investigator Site 2030
🇨🇦Thunder Bay, Ontario, Canada
Investigator Site 2004
🇨🇦Newmarket, Ontario, Canada
Investigator Site 2008
🇨🇦Scarborough, Ontario, Canada
Investigator Site 2012
🇨🇦Toronto, Ontario, Canada
Investigator Site 2011
🇨🇦Toronto, Ontario, Canada
Investigator Site 2074
🇨🇦Laval, Quebec, Canada
Investigator Site 2052
🇨🇦Montreal, Quebec, Canada
Investigator Site 2001
🇨🇦Montreal, Quebec, Canada
Investigator Site 2071
🇨🇦St. Jerome, Quebec, Canada
Investigator Site 2009
🇨🇦Montreal, Quebec, Canada
Investigator Site 2006
🇨🇦Terrebonne, Quebec, Canada
Investigator Site 2053
🇨🇦Quebec, Canada
Investigator Site 2010
🇨🇦Saint John, Canada
Investigator Site 4212
🇨🇿Jihlavska, Brno, Czech Republic
Investigator Site 2007
🇨🇦Quebec, Canada
Investigator Site 4201
🇨🇿Usti nad Labem, Labem, Czech Republic
Investigator Site 4216
🇨🇿Liberec, Stare Mesto, Czech Republic
Investigator Site 4206
🇨🇿Hradec Kralove, Czech Republic
Investigator Site 4208
🇨🇿Jihlava, Czech Republic
Investigator Site 4214
🇨🇿Mlada Boleslav, Czech Republic
Investigator Site 4218
🇨🇿Nymburk, Czech Republic
Investigator 4218
🇨🇿Nymburk, Czech Republic
Investigator Site 4204
🇨🇿Praha 2, Czech Republic
Investigator Site 4217
🇨🇿Praha 5, Czech Republic
Investigator Site 4213
🇨🇿Praha, Czech Republic
Investigator Site 4220
🇨🇿Praha, Czech Republic
Investigator Site 4202
🇨🇿Usti nad Labem, Czech Republic
Investigator Site 9508
🇬🇪Tbilisi, Georgia
Investigator Site 4203
🇨🇿Znojmo, Czech Republic
Investigator Site 9502
🇬🇪Tbilisi, Georgia
Investigator Site 9509
🇬🇪Tbilisi, Georgia
Investigator Site 9510
🇬🇪Tbilisi, Georgia
Investigator Site 4932
🇩🇪Bad Friedrichshall, Germany
Investigator Site 9507
🇬🇪Tbilisi, Georgia
Investigator Site 4930
🇩🇪Bad Nauheim, Germany
Investigator Site 4921
🇩🇪Warendorf, Am Krankenhaus, Germany
Investigator Site 4908
🇩🇪Magdeburg, Germany
Investigator Site 4928
🇩🇪Berlin, Germany
Investigator Site 4905
🇩🇪Bonn, Germany
Investigator Site 4923
🇩🇪Dortmund, Germany
Investigator Site 4922
🇩🇪Hamburg, Germany
Investigator Site 4911
🇩🇪Kiel, Germany
Investigator Site 4901
🇩🇪Limburg, Germany
Investigator Site 4929
🇩🇪Kassel, Germany
Investigator Site 4925
🇩🇪Nauen, Germany
Investigator Site 4906
🇩🇪Ulm, Germany
Investigator Site 4915
🇩🇪Regensburg, Germany
Investigator Site 3626
🇭🇺Pecs, Baranya Megye, Hungary
Investigator Site 3606
🇭🇺Szekesfehervar, Fejer Megye, Hungary
Investigator Site 3602
🇭🇺Budapest, Gaal Jozsef, Hungary
Investigator Site 3614
🇭🇺Semmelweis, Kistarcsa, Hungary
Investigator Site 3605
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Investigator Site 3616
🇭🇺Budapest, Pest Megye, Hungary
Investigator Site 3612
🇭🇺Budapest, Pest Megye, Hungary
Investigator Site 3603
🇭🇺Zalaegerszeg, Zala Megye, Hungary
Investigator Site 3625
🇭🇺Balatonfured, Hungary
Investigator Site 3604
🇭🇺Budapest, Hungary
Investigator Site 3622
🇭🇺Budapest, Hungary
Investigator Site 3619
🇭🇺Eger, Hungary
Investigator Site 3624
🇭🇺Hodmezovasarhely, Hungary
Investigator Site 3623
🇭🇺Szombathely, Hungary
Investigator Site 9109
🇮🇳Secunderabad, Andhra Pradesh, India
Investigator Site 9119
🇮🇳Secunderabad, Andhra Pradesh, India
Investigator Site 9104
🇮🇳Ahmedabad, Gujarat, India
Investigator Site 9111
🇮🇳Ahmedabad, Gujarat, India
Investigator Site 9115
🇮🇳Vadodara, Gujarat, India
Investigator Site 9108
🇮🇳Ahmedabad, Gujarat, India
Investigator Site 9102
🇮🇳Vadodara, Gujarat, India
Investigator Site 9101
🇮🇳Nagpur, Maharashtra, India
Investigator Site 9117
🇮🇳Surat, Gujarat, India
Investigator Site 9114
🇮🇳Bangalore, Karanataka, India
Investigator Site 9121
🇮🇳Bangalore, Karnataka, India
Investigator Site 9103
🇮🇳Lucknow, Uttar Pradesh, India
Investigator Site 9113
🇮🇳Indore, Madhya Pradesh, India
Investigator Site 3908
🇮🇹Cecina, Italy
Investigator Site 3921
🇮🇹Brescia, Via L Bissolati, Italy
Investigator Site 3916
🇮🇹Massa, Italy
Investigator Site 3907
🇮🇹Napoli, Italy
Investigator Site 3906
🇮🇹Milano, Italy
Investigator Site 3901
🇮🇹Monza, Italy
Investigator Site 3902
🇮🇹Rome, Italy
Investigator Site 3903
🇮🇹Rozzano (MI), Italy
Investigator Site 8202
🇰🇷Cheongju, Korea, Republic of
Investigator Site 3909
🇮🇹Rome, Italy
Investigator Site 8205
🇰🇷Busan, Korea, Republic of
Investigator Site 3904
🇮🇹Siena, Italy
Investigator Site 8206
🇰🇷Busan, Korea, Republic of
Investigator Site 8214
🇰🇷Daegu, Korea, Republic of
Investigator Site 8213
🇰🇷Daejeon, Korea, Republic of
Investigator Site 8203
🇰🇷Gwangju, Korea, Republic of
Investigator Site 8204
🇰🇷Gyeonggi-do, Korea, Republic of
Investigator Site 8212
🇰🇷Seoul, Korea, Republic of
Investigator Site 8210
🇰🇷Kangwon-do, Korea, Republic of
Investigator Site 8209
🇰🇷Seoul, Korea, Republic of
Investigator Site 9603
🇱🇧Beirut, Lebanon
Investigator Site 8215
🇰🇷Seoul, Korea, Republic of
Investigator Site 8208
🇰🇷Suwon, Korea, Republic of
Investigator Site 8211
🇰🇷Suwon, Korea, Republic of
Investigator Site 8201
🇰🇷Seoul, Korea, Republic of
Investigator Site 9601
🇱🇧Beirut, Lebanon
Investigator Site 3129
🇳🇱Goes, RA, Netherlands
Investigator Site 3120
🇳🇱Amstelveen, Netherlands
Investigator Site 3126
🇳🇱Nieuwegein, CM, Netherlands
Investigator Site 3117
🇳🇱Amsterdam, Netherlands
Investigator Site 3128
🇳🇱Amsterdam, Netherlands
Investigator Site 3125
🇳🇱Amsterdam, Netherlands
Investigator Site 3130
🇳🇱Delft, Netherlands
Investigator Site 3136
🇳🇱Breda, Netherlands
Investigator Site 3105
🇳🇱Deventer, Netherlands
Investigator Site 3108
🇳🇱Den Helder, Netherlands
Investigator Site 3102
🇳🇱Ede, Netherlands
Investigator Site 3134
🇳🇱Heerlen, Netherlands
Investigator Site 3109
🇳🇱Hoogeveen, Netherlands
Investigator Site 3118
🇳🇱Leiden, Netherlands
Investigator Site 3107
🇳🇱Roosendaal, Netherlands
Investigator Site 3101
🇳🇱Leeuwarden, Netherlands
Investigator Site 3112
🇳🇱Purmerend, Netherlands
Investigator Site 3104
🇳🇱Rotterdam, Netherlands
Investigator Site 3123
🇳🇱Rotterdam, Netherlands
Investigator Site 3106
🇳🇱Rotterdam, Netherlands
Investigator Site 3131
🇳🇱Schiedam, Netherlands
Investigator Site 3103
🇳🇱Tilburg, Netherlands
Investigator Site 3135
🇳🇱Sneek, Netherlands
Investigator Site 3116
🇳🇱Utrecht, Netherlands
Investigator Site 3113
🇳🇱Zaandam, Netherlands
Investigator Site 3124
🇳🇱Venlo, Netherlands
Investigator Site 6402
🇳🇿Takapuna, Auckland, New Zealand
Investigator Site 6405
🇳🇿Christchurch, New Zealand
Investigator Site 4804
🇵🇱Inowroclaw, Kujawsko-pomorskie, Poland
Investigator Site 4828
🇵🇱Gdansk, Pomorskie, Poland
Investigator Site 6404
🇳🇿Dunedin, New Zealand
Investigator Site 6401
🇳🇿Hamilton, New Zealand
Investigator Site 6406
🇳🇿Wellington, New Zealand
Investigator Site4819
🇵🇱Pulawy, Podkarpackie, Poland
Investigator Site 4825
🇵🇱Wroc³aw, Dolnoslaskie, Poland
Investigator Site 4809
🇵🇱Bialystok, Poland
Investigator Site 4801
🇵🇱Bytom, Poland
Investigator Site 4813
🇵🇱Bialystok, Poland
Investigator Site 4827
🇵🇱Szczecin, Poland
Investigator Site 4812
🇵🇱Warszawa, Poland
Investigator Site 4815
🇵🇱Warszawa, Poland
Investigator Site 4823
🇵🇱Warszawa, Poland
Investigator Site 4824
🇵🇱Wroclaw, Poland
Investigator Site 7023
🇷🇺Irkutsk, Russian Federation
Investigator Site 7021
🇷🇺Chelyabinsk, Russian Federation
Investigator Site 7020
🇷🇺Kazan, Russian Federation
Investigator Site 7024
🇷🇺Kursk, Russian Federation
Investigator Site 7002
🇷🇺Kemerovo, Russian Federation
Investigator Site 7003
🇷🇺Moscow, Russian Federation
Investigator Site 7007
🇷🇺Leningrad, Russian Federation
Investigator Site 7017
🇷🇺Krasnoyarsk, Russian Federation
Investigator Site 7015
🇷🇺Moscow, Russian Federation
Investigator Site 7019
🇷🇺Moscow, Russian Federation
Investigator Site 7018
🇷🇺Murmansk, Russian Federation
Investigator Site 7027
🇷🇺Novosibirsk, Russian Federation
Investigator Site 7022
🇷🇺Orenburg, Russian Federation
Investigator Site 7016
🇷🇺Rostov-on-Don, Russian Federation
Investigator Site 7006
🇷🇺Saratov, Russian Federation
Investigator Site 7005
🇷🇺Samara, Russian Federation
Investigator Site 7028
🇷🇺Saratov, Russian Federation
Investigator Site 7025
🇷🇺St. Petersburg, Russian Federation
Investigator Site 7013
🇷🇺St. Petersburg, Russian Federation
Investigator Site 7009
🇷🇺St.Petersburg, Russian Federation
Investigator Site 7012
🇷🇺Tyumen, Russian Federation
Investigator Site 3404
🇪🇸Oviedo, Asturias, Spain
Investigator Site 7011
🇷🇺Tomsk, Russian Federation
Investigator Site 3432
🇪🇸Badalona, Barcelona, Spain
Investigator Site 3411
🇪🇸Lorca, Murcia, Spain
Investigator Site 3418
🇪🇸Barcelona, Spain
Investigator Site 3435
🇪🇸Albacete, Spain
Investigator Site 3406
🇪🇸Girona, Spain
Investigator Site 3410
🇪🇸Vigo, Pontevedra, Spain
Investigator Site 3407
🇪🇸Huelva, Spain
Investigator Site 3428
🇪🇸Barcelona, Spain
Investigator Site 3430
🇪🇸Leganes, Spain
Investigator Site 3402
🇪🇸Lleida, Spain
Investigator Site 3415
🇪🇸Malaga, Spain
Investigator Site 3424
🇪🇸Reus, Spain
Investigator Site 3421
🇪🇸Malaga, Spain
Investigator Site 3401
🇪🇸Madrid, Spain
Investigator Site 3431
🇪🇸Pontevedra, Spain
Investigator Site 3414
🇪🇸Santa Cruz de Tenerife, Spain
Investigator Site 3809
🇺🇦Dnipropetrovsk, Ukraine
Investigator Site 3403
🇪🇸Valencia, Spain
Investigator Site 3422
🇪🇸Utrera, Spain
Investigator Site 3807
🇺🇦Ivano-Frankivsk, Ukraine
Investigator Site 3806
🇺🇦Kharkiv, Ukraine
Investigator Site 3802
🇺🇦Kharkiv, Ukraine
Investigator Site 3803
🇺🇦Kharkiv, Ukraine
Investigator Site
🇺🇦Kharkiv, Ukraine
Investigator Site 3810
🇺🇦Kharkiv, Ukraine
Investigator Site 3801
🇺🇦Kiev, Ukraine
Investigator Site 3808
🇺🇦Kiev, Ukraine
Investigator Site 3805
🇺🇦Kiev, Ukraine
Investigator Site 3813
🇺🇦Odessa, Ukraine
Investigator Site 3811
🇺🇦Lviv, Ukraine
Investigator Site 3814
🇺🇦Poltava, Ukraine
Investigator Site 3815
🇺🇦Odessa, Ukraine
Investigator Site 1028
🇺🇸Newark, Delaware, United States
Investigator Site 1121
🇺🇸Raleigh, North Carolina, United States
Investigator Site 1088
🇺🇸Raleigh, North Carolina, United States
Investigator Site 3409
🇪🇸Madrid, Spain
Investigator Site 3423
🇪🇸Madrid, Spain
Investigator Site 7026
🇷🇺Barnaui, Russian Federation
Investigator Site 1058
🇺🇸Tampa, Florida, United States
Investigator Site 1092
🇺🇸Missoula, Montana, United States
Investigator Site 1022
🇺🇸Clearwater, Florida, United States
Investigator Site 1051
🇺🇸Clearwater, Florida, United States
Investigator Site 1144
🇺🇸Shreveport, Louisiana, United States
Investigator Site 1047
🇺🇸Knoxville, Tennessee, United States
Investigator Site 6112
🇦🇺Douglas, Queensland, Australia
Investigator Site 1031
🇺🇸Ridgewood, New Jersey, United States
Investigator Site 1137
🇺🇸Petoskey, Michigan, United States
Investigator Site 4927
🇩🇪Lubeck, Germany
Investigator Site 3629
🇭🇺Sopron, Hungary
Investigator Site 9110
🇮🇳Hyderabad, Andhra Pradesh, India
Investigator Site 4210
🇨🇿Brno, Czech Republic
Investigator Site 4902
🇩🇪Mainz, Germany
Investigator Site 4917
🇩🇪Munchen, Germany
Investigator Site 3918
🇮🇹Roma, Italy
Investigator Site 4207
🇨🇿Olomouc, Czech Republic
Investigator Site 4209
🇨🇿Ostrava, Czech Republic
Investigator Site 8207
🇰🇷Seoul, Korea, Republic of
Investigator Site 4907
🇩🇪Goettingen, Germany
Investigator Site 7001
🇷🇺Ekaterinburg, Russian Federation
Investigator Site 1014
🇺🇸Jackson, Tennessee, United States
Investigator Site 9118
🇮🇳Kolkata, West Bengal, India